Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Qbrelis, Prinivil, Zestril
Synonyms :
Lisinopril
Class :
ACE Inhibitors
Brand Name :
Qbrelis, Prinivil, Zestril
Synonyms :
Lisinopril
Class :
ACE Inhibitors
Dosage Forms & Strengths
Tablet
2.5 mg
5 mg
10 mg
20 mg
30 mg
40 mg
Solution
1mg/ml
Initial dose: 10 mg orally daily
Maintenance dose: 20-40 mg orally daily
Maximum dose: 80 mg orally daily
Systolic Congestive Heart Failure
2.5-5 mg orally daily; may be increase to 40 mg orally daily
5 mg orally (onset of symptoms of acute MI);
Subsequent dose of 5 mg orally after 24 hours, and 10 mg orally after 48 hours.
and increase 10 mg orally daily 6 weeks.
10 - 20
mg
orally
daily; may be increase to 20-40 mg orally daily
Dosage Forms & Strengths
Tablet
2.5 mg
5 mg
10 mg
20 mg
30 mg
40 mg
Solution
1mg/ml
Age: >6 years
0.07 mg/kg orally daily; increase up to 5 mg once a day; Dosage adjusted for 1–2-week intervals.
may enhance the concentration of serum when combined with lithium
may enhance the concentration of serum when combined with lithium
angiotensin II Receptor Blockers may enhance the adverse/toxic effect of angiotensin-Converting Enzyme Inhibitors
angiotensin II Receptor Blockers may enhance the adverse/toxic effect of angiotensin-Converting Enzyme Inhibitors
angiotensin II Receptor Blockers may enhance the adverse/toxic effect of angiotensin-Converting Enzyme Inhibitors
angiotensin II Receptor Blockers may enhance the adverse/toxic effect of angiotensin-Converting Enzyme Inhibitors
angiotensin II Receptor Blockers may enhance the adverse/toxic effect of angiotensin-Converting Enzyme Inhibitors
may increase the toxic effect of angiotensin receptor II blockers
may increase the toxic effect of angiotensin receptor II blockers
may diminish the serum concentration when combined with angiotensin-converting enzyme inhibitors
may have an increased adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increased adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increased adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increased adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increased adverse effect when combined with angiotensin-converting enzyme inhibitors
sodium ferric gluconate complex
The negative effects of lisinopril, which include allergic reactions, low blood pressure, lightheadedness, fever, flushing, chest discomfort, back pain, rash, itching, nausea, vomiting, and abdominal pain, can occasionally be made worse by medications like sodium ferric gluconate complex.
may have an increased adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increased adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increased adverse effect when combined with angiotensin-converting enzyme inhibitors
may enhance the concentration of serum when combined with lithium
may enhance the concentration of serum when combined with lithium
may diminish the effects of indomethacin by pharmacodynamic antagonism
may diminish the effects of indomethacin by pharmacodynamic antagonism
A decrease in renal function may be seen when aspirin rectal and lisinopril are coadministered due to pharmacodynamic antagonism
angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents
angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents
angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents
angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents
angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents
Enhance the neuromuscular effect of NMBAs
Enhance the neuromuscular effect of NMBAs
Enhance the neuromuscular effect of NMBAs
Enhance the neuromuscular effect of NMBAs
Enhance the neuromuscular effect of NMBAs
anticholinergic agents decrease the efficacy of other ACE inhibitors
anticholinergic agents decrease the efficacy of other ACE inhibitors
anticholinergic agents decrease the efficacy of other ACE inhibitors
anticholinergic agents decrease the efficacy of other ACE inhibitors
anticholinergic agents decrease the efficacy of other ACE inhibitors
may have an increasingly adverse effect when combined with NSAIDs
may have an increasingly adverse effect when combined with NSAIDs
may have an increasingly adverse effect when combined with NSAIDs
may have an increasingly adverse effect when combined with NSAIDs
may have an increasingly adverse effect when combined with NSAIDs
may have an increased therapeutic effect when combined with angiotensin II receptor blocker
may have an increased therapeutic effect when combined with angiotensin II receptor blocker
may have an increased hypotensive effect when combined with angiotensin-converting enzyme inhibitors
may have an increased hypotensive effect when combined with angiotensin-converting enzyme inhibitors
may have an increased hypotensive effect when combined with angiotensin-converting enzyme inhibitors
may increase the risk of neutropenia
choline magnesium trisalicylate
salicylates may enhance the nephrotoxic effect of ACE Inhibitors
may increase the toxic effects
may increase the toxic effects
may increase the toxic effects
may increase the toxic effects
may increase the toxic effects
Icatibant may diminish the effect of ACE Inhibitors
choline magnesium trisalicylate
may enhance the nephrotoxic effect of ACE inhibitors
may have an increasingly adverse effect when combined with alteplase
polyethylene glycol and electrolytes
They may increase the nephrotoxic effect when combined with polyethylene Glycol-electrolyte Solution
Dipeptidyl Peptidase-IV Inhibitors: they may increase the toxic effect of angiotensin-converting enzyme inhibitors
Dipeptidyl Peptidase-IV Inhibitors: they may increase the toxic effect of angiotensin-converting enzyme inhibitors
may enhance the hyperkalemic effect
may enhance the hyperkalemic effect
may enhance the hyperkalemic effect
Nonsteroidal Anti-Inflammatory Agents: they may decrease the therapeutic effect of Angiotensin-Converting Enzyme Inhibitors
Nonsteroidal Anti-Inflammatory Agents: they may decrease the therapeutic effect of Angiotensin-Converting Enzyme Inhibitors
Nonsteroidal Anti-Inflammatory Agents: they may decrease the therapeutic effect of Angiotensin-Converting Enzyme Inhibitors
Nonsteroidal Anti-Inflammatory Agents: they may decrease the therapeutic effect of Angiotensin-Converting Enzyme Inhibitors
Nonsteroidal Anti-Inflammatory Agents: they may decrease the therapeutic effect of Angiotensin-Converting Enzyme Inhibitors
may have an increasingly adverse effect when combined with iron dextran complex
spironolactone and hydrochlorothiazide
may have an increased hyperkalemic effect when combined with angiotensin-converting enzyme inhibitors
may have an increased hyperkalemic effect when combined with angiotensin-converting enzyme inhibitors
may have an increased hyperkalemic effect when combined with angiotensin-converting enzyme inhibitors
may have an increased hyperkalemic effect when combined with angiotensin-converting enzyme inhibitors
may have an increased hyperkalemic effect when combined with angiotensin-converting enzyme inhibitors
choline magnesium trisalicylate
may have an increased nephrotoxic effect when combined with angiotensin-converting enzyme inhibitors
may have an increased hypotensive effect when combined with angiotensin-converting enzyme inhibitors
may have an increased hypotensive effect when combined with angiotensin-converting enzyme inhibitors
may have an increased hyperkalemic effect when combined with angiotensin-converting enzyme inhibitors
may have an increased hypotensive effect when combined with ACE inhibitors
may have an increased hypotensive effect when combined with ACE inhibitors
may have an increased hypotensive effect when combined with ACE inhibitors
the risk of angioedema may be increased
probenecid may enhance the effects of lisinopril through an unidentified interaction mechanism
angiotensin II receptor blockers increase the toxicity of ACE inhibitors
angiotensin II receptor blockers increase the toxicity of ACE inhibitors
angiotensin II receptor blockers increase the toxicity of ACE inhibitors
angiotensin II receptor blockers increase the toxicity of ACE inhibitors
angiotensin II receptor blockers increase the toxicity of ACE inhibitors
Action and Spectrum:
Lisinopril is an angiotensin converting enzyme (ACE) inhibitors that block angiotensin conversion and reduces heart workload which inhibits bradykinin metabolism.
Adverse reaction:
>10%
Heart failure
Hypertension
Cough
Dizziness
Hypotension
1-10%
Heart failure
Creatinine increased
Rash
Infection
Syncope
Chest pain
Abdominal pain
≥1%
Asthenia
Cough
Pruritus
Hypertension
Angina pectoris
Nausea
Headache
Dizziness
Hypotension
≥1%
Fatigue, asthenia
Pancreatitis, constipation
Flatulence
Visual loss
Tinnitus, photophobia
Taste disturbances
<1%
Cough
Angioedema
Black box warning:
In pregnancy cases, stop taking this drug because it causes fetal harm.
Contraindications/caution:
Contraindications:
Cautions:
Pregnancy Warnings:
Pregnancy category: N/A
Lactation: Excretion of the drug into the human breast milk is unknown
Pregnancy categories:
Category A: Satisfactory and well-controlled studies show no evidence of risk to the fetus in the first trimester or in the later trimester.
Category B: No evidence of risk to fetus found in animal reproduction studies and there are not enough studies on pregnant women.
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for an effect in humans, care must be taken for potential risks in pregnant women.
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite potential risks may be used only in emergency cases for potential benefits.
Category X: Drugs listed in this category clearly outweigh risks over benefits. Hence, these categories of drugs need to be avoided by pregnant women.
Category N: No data for the drug under this category is available.
Pharmacology:
Lisinopril prevents conversion of angiotensin I to angiotensin II inhibitor that reduces smooth muscle cell proliferation. The drug decrease blood pressure, which reduce the risk of heart attack and stroke.
Pharmacodynamics:
Lisinopril increases urine output with help of reduced aldosterone levels, that leads to decreased sodium re-absorption in the kidneys. This shows enhanced excretion of sodium and water.
Pharmacokinetics:
Absorption
It is absorbed rapidly, peak plasma concentrations reach in 6 to 8 hours
Distribution
Volume of distribution shows ~ 124 L.
Excretion and elimination
The metabolites excreted in the urine with 95% of the dose excreted unchanged.
Administration:
Lisinopril tablets can be taken orally with water.
Patient information leaflet:
Generic name: Lisinopril
Why do we use Lisinopril?
Lisinopril is an anti-hypertensive drug which belongs to the subclass angiotensin converting enzyme inhibitors used to treat hypertension.
It is used to decrease high blood pressure also it prevents risk of heart stroke and heart attacks.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
